Adenosine Receptor A3 (ADORA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 63 pages | ID: ACF9611C8BEEEN
Global Markets Direct

Abstracts

Adenosine Receptor A3 (ADORA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Adenosine Receptor A3 - Drugs In Development, 2022, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 1, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Immunology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Male Health, Oncology, Central Nervous System, Musculoskeletal Disorders, Ophthalmology and Women's Health which include indications Non-Alcoholic Steatohepatitis (NASH), Hepatocellular Carcinoma, Inflammation, Kidney Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Psoriasis, Rheumatoid Arthritis, Arthritis, Autoimmune Disorders, Chronic Kidney Disease (Chronic Renal Failure), Colon Cancer, Diabetic Nephropathy, Erectile Dysfunction, Female Sexual Dysfunction, Glaucoma, Male Sexual Dysfunction, Melanoma, Ocular Hypertension, Osteoarthritis Pain, Plaque Psoriasis (Psoriasis Vulgaris), Post-Operative Pain, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Prostate Cancer and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
• The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects
• The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

Contents

Introduction
Global Markets Direct Report Coverage
Adenosine Receptor A3 (ADORA3) - Overview
Adenosine Receptor A3 (ADORA3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
Can-Fite BioPharma Ltd
Future Medicine Co Ltd
Neumentum Inc
Palo BioFarma SL
Protheragen Inc
Adenosine Receptor A3 (ADORA3) - Drug Profiles
Cannabinoids - Drug Profile
Product Description
Mechanism Of Action
History of Events
CF-602 - Drug Profile
Product Description
Mechanism Of Action
History of Events
DPP-017 - Drug Profile
Product Description
Mechanism Of Action
FM-1203 - Drug Profile
Product Description
Mechanism Of Action
LJ-1888 - Drug Profile
Product Description
Mechanism Of Action
LJ-2698 - Drug Profile
Product Description
Mechanism Of Action
History of Events
namodenoson - Drug Profile
Product Description
Mechanism Of Action
History of Events
NTM-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PBF-1650 - Drug Profile
Product Description
Mechanism Of Action
History of Events
PBF-677 - Drug Profile
Product Description
Mechanism Of Action
History of Events
piclidenoson - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
Adenosine Receptor A3 (ADORA3) - Dormant Products
Adenosine Receptor A3 (ADORA3) - Discontinued Products
Adenosine Receptor A3 (ADORA3) - Product Development Milestones
Featured News & Press Releases
Jul 11, 2022: Can-Fite to submit FDA & EMA registration plans for piclidenoson in the oral treatment of moderate to severe psoriasis
Jun 29, 2022: Can-Fite announces positive top-line results from piclidenoson phase III COMFORT study in moderate to severe psoriasis
Jun 24, 2022: Can-Fite’s CF602 reverses erectile dysfunction in diabetic pre-clinical model: study published in peer-reviewed Journal Andrologia
Jun 09, 2022: Can-Fite announces publication of clinical study data for piclidenoson and namodenoson in scientific journal
May 16, 2022: Can-Fite granted key NASH Patent in Israel
May 02, 2022: Can-Fite’s CEO to present Namodenoson’s efficacy in liver cancer as expert speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit
Apr 05, 2022: Can-Fite is developing a topical Piclidenoson psoriasis treatment that shows efficacy in a preclinical model: potential complementary product to its phase III oral psoriasis drug
Mar 28, 2022: Can-Fite to present at Dermatology Drug Development Summit Europe on April 6, 2022
Mar 14, 2022: Can-Fite: Namodenoson’s treatment of liver fibrosis receives Notice of Allowance from U.S. Patent Office
Mar 08, 2022: Can-Fite’s phase III psoriasis study data expected Q2 2022
Feb 01, 2022: Can-Fite enrols first subject in Phase IIb NASH trial
Jan 13, 2022: Prior to phase III psoriasis data release Can Fite reports that piclidenoson destroys pathological skin cells in vitro
Jan 10, 2022: Can-Fite to conduct investor meetings during the J.P. Morgan Healthcare Conference
Dec 29, 2021: Following complete clearance of cancer lesions in advanced liver cancer patient, Can-Fite is filing patent applications for the treatment of various advanced solid tumors
Dec 20, 2021: Liver cancer patient treated with Can-Fite’s namodenoson clears all cancer lesions under open label extension of phase II Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Can-Fite BioPharma Ltd, 2022
Pipeline by Future Medicine Co Ltd, 2022
Pipeline by Neumentum Inc, 2022
Pipeline by Palo BioFarma SL, 2022
Pipeline by Protheragen Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022